A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose

A. Jantikar, B. Brashier, A. Raghupathy, T. Bal, P. Mahadik, P. Gokhale, J. Gogtay, S. S. Salvi (Pune, Mumbai, India)

Source: Annual Congress 2005 - Bronchodilators with and without corticosteroids
Session: Bronchodilators with and without corticosteroids
Session type: Thematic Poster Session
Number: 837
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Jantikar, B. Brashier, A. Raghupathy, T. Bal, P. Mahadik, P. Gokhale, J. Gogtay, S. S. Salvi (Pune, Mumbai, India). A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose. Eur Respir J 2005; 26: Suppl. 49, 837

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler
Source: Eur Respir J 2001; 17: 225-232
Year: 2001



Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 125s
Year: 2005

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020



Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005

Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg
Source: International Congress 2017 – Inhalers and their use
Year: 2017

Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide?
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 52s
Year: 2003